Medtronic (NYSE:MDT) today announced positive results from a study of its next-generation MiniMed 780G automated insulin delivery system. Results from the ADAPT study, published in The Lancet Diabetes & Endocrinology, demonstrated improved glycemic control and treatment satisfaction among users of MiniMed 780G. The MiniMed 780G system is available in more than 60 countries. It is currently […]
Clinical Trials
Study shows workplace productivity improvements with One Drop type 2 diabetes tech
One Drop today announced positive results from a trial of its digital health platform for people with type 2 diabetes. Employees using the One Drop digital diabetes management platform experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups. One Drop’s platform uses AI to provide […]
PhysIQ, InCarda Therapeutics to collaborate on AFib treatment tech
PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics. Newark, California-based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases. Get the full story at our sister site, MassDevice.
First U.S. patient enrolled in MedAlliance Selution SLR drug-eluting balloon trial
MedAlliance announced today that the first U.S. patient was enrolled in a U.S. clinical trial of its novel sirolimus-eluting balloon. Geneva, Switzerland-based MedAlliance received FDA investigational device exemption (IDE) approval for its Selution SLR drug-eluting balloon in the below-the-knee procedures. One week later, the company enrolled the first patient in its multi-center FDA Selution4BTK trial in […]
Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
Better Therapeutics (Nasdaq:BTTX) posted second-quarter quarter results today that beat the consensus forecast on Wall Street as it prepared to submit its first product for FDA review. Better Therapeutics has not yet generated revenue from the commercialization or sale of any product. The company went public through a special purpose acquisition company merger in October. […]
MedAlliance wins second FDA IDE nod for drug-coated balloon
MedAlliance announced today that received conditional FDA investigational device exemption (IDE) for its Selution SLR system. The FDA IDE nod for the novel sirolimus-eluting balloon allows MedAlliance to initiate a pivotal clinical trial for use of Selution SLR in the treatment of occlusive disease of the superficial femoral artery (SFA). Geneva, Switzerland-based MedAlliance’s second IDE […]
How Medtronic aims to address health inequities in diabetes
Fueled by personal experience, Maribel Baker leads Medtronic’s diabetes business toward improving health equity. At 15 years old, Maribel Baker’s life was in the balance. While growing up in Panama, Baker had to undergo leg surgery because she was born with one leg shorter than the other. Following the surgery, she learned that she had […]
Concept Medical begins enrollment for sirolimus-coated balloon trial
Concept Medical announced today that it has already enrolled 15 patients in a trial of its drug-coated balloon (DCB) for peripheral artery disease (PAD). Tampa, Florida-based Concept Medical’s LIMES prospective multi-center randomized controlled trial to evaluate the safety and efficacy of below-the-knee (BTK) sirolimus drug-coated balloon against standard angioplasty for the treatment of infrapopliteal occlusions […]
Better Therapeutics completes trial for type 2 diabetes treatment, will submit to FDA
Better Therapeutics (Nasdaq:BTTX) announced today that it completed the pivotal trial for its BT-001 digital therapeutic for diabetes. San Francisco-based Better Therapeutics designed its nutritional cognitive behavioral therapy (nCBT) platform to address the root causes of cardiometabolic diseases. It designed its investigational, first-in-class BT-001 prescription digital therapeutic (PDT) to use nCBT to treat type 2 […]
AbbVie enters partnership with iStar with option to acquire
AbbVie (NYSE:ABBV) announced today that it entered into a strategic alliance with iStar Medical over the MINIject device. The strategic transaction centers around helping to further develop and commercialize iStar’s MINIject minimally invasive glaucoma surgical (MIGS) device. It will also provide AbbVie with a chance to expand its eye care business through an option to […]
